AU2013235340B2 - Fast diagnosis and personalized treatments for acne - Google Patents

Fast diagnosis and personalized treatments for acne Download PDF

Info

Publication number
AU2013235340B2
AU2013235340B2 AU2013235340A AU2013235340A AU2013235340B2 AU 2013235340 B2 AU2013235340 B2 AU 2013235340B2 AU 2013235340 A AU2013235340 A AU 2013235340A AU 2013235340 A AU2013235340 A AU 2013235340A AU 2013235340 B2 AU2013235340 B2 AU 2013235340B2
Authority
AU
Australia
Prior art keywords
seq
acne
locus
acnes
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013235340A
Other languages
English (en)
Other versions
AU2013235340A1 (en
Inventor
Sorel T. Fitz-Gibbon
Huiying Li
Jeffery F. Miller
Robert L. Modlin
Shuta Tomida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2013235340A1 publication Critical patent/AU2013235340A1/en
Application granted granted Critical
Publication of AU2013235340B2 publication Critical patent/AU2013235340B2/en
Priority to AU2019219817A priority Critical patent/AU2019219817A1/en
Priority to AU2020227049A priority patent/AU2020227049A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013235340A 2012-03-17 2013-03-15 Fast diagnosis and personalized treatments for acne Ceased AU2013235340B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019219817A AU2019219817A1 (en) 2012-03-17 2019-08-22 Fast diagnosis and personalized treatments for acne
AU2020227049A AU2020227049A1 (en) 2012-03-17 2020-09-02 Fast diagnosis and personalized treatments for acne

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612290P 2012-03-17 2012-03-17
US61/612,290 2012-03-17
PCT/US2013/032551 WO2013142378A1 (en) 2012-03-17 2013-03-15 Fast diagnosis and personalized treatments for acne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019219817A Division AU2019219817A1 (en) 2012-03-17 2019-08-22 Fast diagnosis and personalized treatments for acne

Publications (2)

Publication Number Publication Date
AU2013235340A1 AU2013235340A1 (en) 2014-10-16
AU2013235340B2 true AU2013235340B2 (en) 2019-05-23

Family

ID=49223275

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013235340A Ceased AU2013235340B2 (en) 2012-03-17 2013-03-15 Fast diagnosis and personalized treatments for acne
AU2019219817A Abandoned AU2019219817A1 (en) 2012-03-17 2019-08-22 Fast diagnosis and personalized treatments for acne
AU2020227049A Abandoned AU2020227049A1 (en) 2012-03-17 2020-09-02 Fast diagnosis and personalized treatments for acne

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019219817A Abandoned AU2019219817A1 (en) 2012-03-17 2019-08-22 Fast diagnosis and personalized treatments for acne
AU2020227049A Abandoned AU2020227049A1 (en) 2012-03-17 2020-09-02 Fast diagnosis and personalized treatments for acne

Country Status (9)

Country Link
US (5) US20150086581A1 (enExample)
EP (3) EP3692999A1 (enExample)
JP (3) JP2015512255A (enExample)
CN (2) CN104364394B (enExample)
AU (3) AU2013235340B2 (enExample)
BR (1) BR112014023005A2 (enExample)
CA (1) CA2867621A1 (enExample)
SG (1) SG11201405783VA (enExample)
WO (1) WO2013142378A1 (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP3692999A1 (en) 2012-03-17 2020-08-12 The Regents of the University of California Fast diagnosis and personalized treatments for acne
CN105593372A (zh) 2013-06-18 2016-05-18 普罗皮肤检测股份有限公司 基于皮肤菌群的分析的定制皮肤护理品和个人护理品
GB2535034A (en) 2013-07-21 2016-08-10 Whole Biome Inc Methods and systems for microbiome characterization, monitoring and treatment
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
KR20230054509A (ko) 2013-11-07 2023-04-24 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
EP3139939B1 (en) * 2014-05-07 2023-09-06 The Regents of The University of California Compositions and methods for treating skin and mucous membrane diseases
PL3158054T3 (pl) 2014-06-17 2025-07-21 Crown Laboratories, Inc. Bakterie zmodyfikowane genetycznie i sposoby modyfikacji genetycznej bakterii
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US9970030B2 (en) 2014-08-27 2018-05-15 Caribou Biosciences, Inc. Methods for increasing CAS9-mediated engineering efficiency
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
WO2016168350A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10774305B2 (en) 2015-04-20 2020-09-15 S-Biomedic Nv Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
JP6046849B1 (ja) * 2015-07-21 2016-12-21 ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法
CA2992828A1 (en) * 2015-08-06 2017-02-09 Ares Genetics Gmbh Genetic resistance prediction against antimicrobial drugs in microorganism using structural changes in the genome
CN108348166B (zh) * 2015-09-09 2022-06-03 普梭梅根公司 用于与抗生素使用相关的感染性疾病及其它健康状况的源自微生物群系的诊断及治疗方法和系统
US20190136298A1 (en) * 2015-09-09 2019-05-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for eczema
CN108348167B (zh) * 2015-09-09 2022-06-03 普梭梅根公司 用于脑-颅面健康相关病症的源自微生物群系的诊断及治疗方法和系统
US10679725B2 (en) 2015-09-17 2020-06-09 Prodermiq, Inc. Predicting skin age based on the analysis of skin flora and lifestyle data
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
JP6872222B2 (ja) * 2015-11-04 2021-05-19 学校法人慶應義塾 対象物の使用者を判定する方法
GB2544481B (en) * 2015-11-16 2019-12-11 Century International Enterprises Ltd A wearable article and a method for producing a wearable article
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
JP2019509263A (ja) * 2016-02-05 2019-04-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の健康増進用組成物及び健康増進方法
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
CN109715179A (zh) * 2016-04-21 2019-05-03 内科德生物群系公司 用于治疗皮肤病症的组合物和方法
EP3445844A4 (en) * 2016-04-21 2019-11-13 Naked Biome, Inc. SYNTHETIC BACTERIA AND METHODS OF USE
WO2017189614A1 (en) * 2016-04-25 2017-11-02 uBiome, Inc. Method and system for characterizing skin related conditions
EP3243907A1 (en) * 2016-05-13 2017-11-15 Curetis GmbH Stable pan-genomes and their use
EP3458079A4 (en) * 2016-05-15 2020-03-04 Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING ACNE
CN106167820A (zh) * 2016-05-19 2016-11-30 胤安国际（辽宁）基因科技股份有限公司 鉴定或辅助鉴定痤疮丙酸杆菌的专用引物及其应用
CN113481294B (zh) * 2016-07-08 2024-03-12 花王株式会社 核酸样品的制备方法
US11913061B2 (en) 2016-07-08 2024-02-27 Kao Corporation Method for preparing nucleic acid sample
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
EP3528825B1 (en) 2016-10-19 2021-07-14 S-Biomedic NV Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
JP6815006B2 (ja) 2016-11-01 2021-01-20 株式会社桃谷順天館 アクネ菌株選択的抗菌剤
WO2018089337A1 (en) * 2016-11-08 2018-05-17 The Regents Of The University Of California Compositions and methods for treating skin diseases and maintaining healthy skin
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11915795B2 (en) * 2016-12-23 2024-02-27 The Regents Of The University Of California Method and device for digital high resolution melt
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
KR20200019116A (ko) 2017-03-10 2020-02-21 프로더믹, 인코포레이티드 피부 균총의 분석에 기반한 맞춤형 피부 케어 제품 및 개인 케어 제품
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018195415A1 (en) * 2017-04-21 2018-10-25 Phi Therapeutics, Inc. Compositions comprising propionibacterium acnes bacteriophages for treating acne
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
WO2019079612A1 (en) * 2017-10-20 2019-04-25 Naked Biome, Inc. SYSTEMS AND METHODS OF BACTERIAL DETECTION AND TREATMENT
CA3084952A1 (en) * 2017-12-05 2019-06-13 Biomx Ltd. Bacteriophage treatment for acne and biofilms
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
JP7626515B2 (ja) * 2018-11-01 2025-02-07 花王株式会社 被験体の皮膚細胞に由来する核酸の調製方法
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
JP7341310B2 (ja) * 2019-07-10 2023-09-08 ジャン・ルオウェイ 皮膚分析のための画像処理、皮膚分析を視覚化するためのシステム及び方法
EP3764370B1 (fr) * 2019-07-12 2024-09-04 bioMérieux Procédé d'identification et de surveillance épidémiologique d'un foyer bactérien
KR102789582B1 (ko) 2019-07-16 2025-03-31 멜리오랩스 인코포레이티드 단일-세포 기반 디지털 고해상도 용융을 위한 방법 및 장치
EP4003381A4 (en) * 2019-07-22 2024-02-28 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20220380744A1 (en) * 2019-10-31 2022-12-01 University Of Maryland, College Park Method of treating infections by bacteriolytic enzymes and manufacture thereof
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
US12102710B2 (en) 2020-06-23 2024-10-01 Crown Laboratories, Inc. Probiotic skin formulations
JP2024512491A (ja) * 2021-03-19 2024-03-19 パラレル・ヘルス・インコーポレイテッド マイクロバイオーム同定およびバクテリオファージ製剤
CN113066533B (zh) * 2021-04-02 2023-04-04 欧蒙医学诊断（中国）有限公司 一种mNGS病原体数据分析方法
CN118737269B (zh) * 2024-08-30 2024-11-19 墨卓生物科技(浙江)有限公司 在单细胞微生物基因组测序结果中区分菌株的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105592A2 (en) * 2008-02-19 2009-08-27 Hogan James J Compositions and methods for detection of propionibacterium acnes nucleic acid

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670777B2 (en) 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
US5836999A (en) 1995-09-28 1998-11-17 Esc Medical Systems Ltd. Method and apparatus for treating psoriasis using pulsed electromagnetic radiation
EP0895534A1 (en) 1996-04-15 1999-02-10 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
JPH11171783A (ja) 1997-08-15 1999-06-29 Vetoquinol Sa 所定の動物に関して細胞性免疫と体重増加を生じる濃度でのバクテリアの経口投与
CA2329057A1 (en) * 1998-05-22 1999-12-02 Creatogen Gmbh Demonstrating resistance to antibiotics in microorganisms
US6726913B1 (en) 1999-10-15 2004-04-27 The Van Kampen Group, Inc. Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
AU2001255524A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US20040157837A1 (en) 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
NZ539076A (en) * 2005-03-29 2008-05-30 Blis Technologies Ltd Skin treatment compositions
EP1907534B2 (en) * 2005-07-12 2024-04-10 Micreos B.V. Bacteriophage and their uses
WO2007056680A2 (en) 2005-11-03 2007-05-18 Forsyth Dental Infirmary For Children Methods and arrays for identifying human microflora
JP5201818B2 (ja) * 2006-11-10 2013-06-05 キヤノン株式会社 プローブセット、プローブ固定担体及び遺伝子検査方法
US7919250B2 (en) 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
EP2082736A1 (fr) * 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
CA2776949A1 (en) 2008-12-05 2010-06-10 The Regents Of The University Of California Methods and compositions for treating p.acnes
US9457077B2 (en) * 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US8784830B2 (en) * 2010-05-27 2014-07-22 Kenichiro Hasumi Antigen peptide and use thereof
EP3692999A1 (en) * 2012-03-17 2020-08-12 The Regents of the University of California Fast diagnosis and personalized treatments for acne
EP2664919A1 (fr) * 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
JP2015524653A (ja) * 2012-07-13 2015-08-27 ロレアル 対象における薄皮状態のインビトロ診断方法及び関連用途
MX2015001751A (es) 2012-08-07 2015-11-13 Topgenix Inc Composicion topica comprendiendo bacterias transformadas que expresan un compuesto de interes.
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102222273B1 (ko) * 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
EP3074027B1 (en) * 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP3139939B1 (en) 2014-05-07 2023-09-06 The Regents of The University of California Compositions and methods for treating skin and mucous membrane diseases
PL3158054T3 (pl) * 2014-06-17 2025-07-21 Crown Laboratories, Inc. Bakterie zmodyfikowane genetycznie i sposoby modyfikacji genetycznej bakterii
EP3328417A4 (en) * 2015-07-31 2019-02-06 The Regents of The University of California MYCOBACTERIUM LYSTERASE: A NEW TREATMENT FOR AKNE
JP2019509263A (ja) * 2016-02-05 2019-04-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の健康増進用組成物及び健康増進方法
CN109715179A (zh) * 2016-04-21 2019-05-03 内科德生物群系公司 用于治疗皮肤病症的组合物和方法
EP3458079A4 (en) * 2016-05-15 2020-03-04 Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING ACNE
EP3528825B1 (en) * 2016-10-19 2021-07-14 S-Biomedic NV Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
CA3084952A1 (en) * 2017-12-05 2019-06-13 Biomx Ltd. Bacteriophage treatment for acne and biofilms
US12102710B2 (en) * 2020-06-23 2024-10-01 Crown Laboratories, Inc. Probiotic skin formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105592A2 (en) * 2008-02-19 2009-08-27 Hogan James J Compositions and methods for detection of propionibacterium acnes nucleic acid

Also Published As

Publication number Publication date
WO2013142378A1 (en) 2013-09-26
US20240117446A1 (en) 2024-04-11
AU2013235340A1 (en) 2014-10-16
EP2825676B1 (en) 2017-12-20
US10364473B2 (en) 2019-07-30
CA2867621A1 (en) 2013-09-26
JP2021013395A (ja) 2021-02-12
AU2020227049A1 (en) 2020-09-17
SG11201405783VA (en) 2014-10-30
EP2825676A1 (en) 2015-01-21
HK1207402A1 (en) 2016-01-29
US20150086581A1 (en) 2015-03-26
BR112014023005A2 (pt) 2017-07-18
US11692229B2 (en) 2023-07-04
US20210123092A1 (en) 2021-04-29
WO2013142378A9 (en) 2014-01-23
JP2015512255A (ja) 2015-04-27
EP3692999A1 (en) 2020-08-12
EP2825676A4 (en) 2015-09-30
CN104364394B (zh) 2019-02-22
CN104364394A (zh) 2015-02-18
CN110055320A (zh) 2019-07-26
EP3360560A1 (en) 2018-08-15
US20190316183A1 (en) 2019-10-17
AU2019219817A1 (en) 2019-09-12
US20170058328A1 (en) 2017-03-02
JP2019050833A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
US20240117446A1 (en) Fast diagnosis and personalized treatments for acne
Meehan et al. Molecular epidemiology of group B streptococci in Ireland reveals a diverse population with evidence of capsular switching
Liu et al. The diversity and host interactions of Propionibacterium acnes bacteriophages on human skin
Chaguza et al. Mechanisms and impact of genetic recombination in the evolution of Streptococcus pneumoniae
Fittipaldi et al. Full-genome dissection of an epidemic of severe invasive disease caused by a hypervirulent, recently emerged clone of group A Streptococcus
Uchiya et al. Comparative genome analyses of Mycobacterium avium reveal genomic features of its subspecies and strains that cause progression of pulmonary disease
Springman et al. Pilus distribution among lineages of group b streptococcus: an evolutionary and clinical perspective
Tokajian et al. Molecular characterization of Staphylococcus aureus in Lebanon
Tulyaprawat et al. Emergence of multi-drug resistance and its association with uncommon serotypes of Streptococcus agalactiae isolated from non-neonatal patients in Thailand
Schindler et al. Group B streptococcus virulence factors associated with different clinical syndromes: Asymptomatic carriage in pregnant women and early-onset disease in the newborn
Di Mento et al. A retrospective molecular epidemiological scenario of carbapenemase-producing Klebsiella pneumoniae clinical isolates in a Sicilian transplantation hospital shows a swift polyclonal divergence among sequence types, resistome and virulome
Alhamami et al. Genomic profiling of Pasteurella multocida isolated from feedlot cases of bovine respiratory disease
Yu et al. Molecular characteristics of Streptococcus pyogenes isolated from Chinese children with different diseases
WO2010062897A1 (en) Methods and compositions to detect clostridium difficile
He et al. Molecular characterization and antimicrobial susceptibility for 62 isolates of Bordetella pertussis from children
Usein et al. Molecular characterization of adult-colonizing Streptococcus agalactiae from an area-based surveillance study in Romania
HK40011589A (en) Fast diagnosis and personalized treatments for acne
HK1207402B (zh) 痤疮的快速诊断和个体化治疗
Khan Detailed genomic and antimicrobial resistance comparison of UK Streptococcus agalactiae isolates from adults to those of diverse global origins
Arteaga Ortega et al. Genomic characterization of the non-O1/non-O139 Vibrio cholerae strain that caused a gastroenteritis outbreak in Santiago, Chile, 2018
JP2009515525A (ja) Ｕｓａ３００市中感染メチシリン−耐性黄色ブドウ球菌の同定
Mir et al. Research Article Supershed Escherichia coli O157: H7 Has Potential for Increased Persistence on the Rectoanal Junction Squamous Epithelial Cells and Antibiotic Resistance
Schiff The Bacterial and Viral Complexity of Postinfectious Hydrocephalus in Uganda
Kadiroğlu Detection of staphylococcus aureus using quqntitative real-time polymerase chain reaction and loop-mediated isothermal amplification methods in Turkish white cheese
Proud Examining the Role of Transformation in the Acquisition of Resistance and Rescue of Genomes from Oxidative Stress

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired